MiSeqDx

Compare MiSeqDx and MiSeq Systems
Compare MiSeqDx and MiSeq Systems

Choose between the MiSeqDx System, which offers both diagnostic and research modes, and the MiSeq System, which is for research use only.


*Report generation is only available for the MiSeqDx Cystic Fibrosis 139-Variant Assay, the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and the Extended RAS Panel.

540 Mb–15 Gb

output range

12-25 million

reads per run

2 × 300 bp

max read length
Interested in receiving newsletters, case studies, and information from Illumina based on your area of interest? Sign up now.
MiSeqDx Cystic Fibrosis 139-Variant Assay
MiSeqDx Cystic Fibrosis 139-Variant Assay

FDA-cleared NGS assay with the largest panel of clinically relevant, functionally validated cystic fibrosis variants in a diverse population.

MiSeqDx Cystic Fibrosis Clinical Sequencing Assay
MiSeqDx Cystic Fibrosis Clinical Sequencing Assay

FDA-cleared next-generation sequencing assay provides a full view of coding regions of the CFTR gene, to aid in in vitro diagnosis of cystic fibrosis.

Extended RAS Panel
Extended RAS Panel

The first FDA-approved NGS in vitro diagnostic for evaluating RAS mutations in colorectal cancer to determine patient eligibility for treatment with Vectibix®.

TruSeq Custom Amplicon Kit Dx
TruSeq Custom Amplicon Kit Dx

A validated, FDA-regulated and CE-IVD-marked kit enabling clinical laboratories to design their own next-generation sequencing assays for use on the MiSeqDx and NextSeq 550Dx systems.


The MiSeqDx instrument is intended for targeted sequencing of DNA libraries from human genomic DNA extracted from peripheral whole blood or formalin-fixed, paraffin-embedded (FFPE) tissue, when used for in vitro diagnostic (IVD) assays performed on the instrument. The MiSeqDx instrument is not intended for whole genome or de novo sequencing. The MiSeqDx instrument is to be used with registered and listed, cleared, or approved IVD reagents and analytical software.